The takeaway
Avanos Medical Inc shows a moderate seasonal pattern over 10 years of data — strongest in February (+2.2%) and softest in September (−2.1%).
Right now
In July, the stock has risen 60% of years, averaging +1.0%, roughly 1.2 pts behind the S&P 500.
The full picture
Avanos Medical Inc's most dependable month has been February, higher in 7 of 10 years; September has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in February (+2.4 pts); it has trailed the market most in March (−4.7 pts).
“vs S&P” is Avanos Medical Inc’s average for a month minus the S&P 500’s average for that same month — isolating Avanos Medical Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, February has closed higher 40% of the time versus 70% across the last 10 years — the pattern is weakening.
Figures are the typical (median) February return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
The seasonal story is really one month's story — February. It has closed higher in 7 of 10 Februaries, a concentration the rest of the calendar can't touch.
A typical February brings +1.1%, a shade under the +2.2% average. That reliability comes with real swings, mind — even February ranges by 9.0% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — February has outpaced the S&P 500 by +2.4 points on average. It is the more striking for the company it keeps — February is a losing month for most of the market, where barely 49% of names gain ground.
It doesn't stand entirely alone — January, June, and July have leaned firm as well, if less emphatically. At the other end of the calendar, September has been the soft spot — the weakest of 6 months that average a loss (−2.1%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, October, and January. Its roughest month on record was a −24.3% January in 2016 — a reminder of how hard even a seasonal name can fall.
At its steadiest, February strung together 7 straight positive years. The pattern has softened of late, February's last five years slipping below its longer-run record.
For a stock this dependable in February, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on.
Short answers on the stock's best month (February), its worst (September), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2016 its best month (February, +2.2%) has run well ahead of its worst (September, −2.1%) — the heatmap above shows how steady that gap has been year to year.
February has been the strongest, averaging +2.2% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −2.1% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade